Loading…
Immunopotentiation of bovine herpes virus subunit vaccination by interleukin-2
Cattle were immunized with glycoprotein IV (gIV) from bovine herpes virus-1 (BHV-1). Groups of five animals were then given either 2, 3, 4, or 5 doses of interleukin-2 (IL-2) (0.5 microgram/kg) at 12-hr intervals. Animals that received no IL-2 exhibited specific immune responses that are typical for...
Saved in:
| Published in: | Immunology 1991-11, Vol.74 (3), p.461-466 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | 466 |
| container_issue | 3 |
| container_start_page | 461 |
| container_title | Immunology |
| container_volume | 74 |
| creator | HUGHES, H. P. A CAMPOS, M GODSON, D. L VAN DRUNEN LITTEL-VAN DEN HURK, S MCDOUGALL, L RAPIN, N ZAMB, T BABIUK, L. A |
| description | Cattle were immunized with glycoprotein IV (gIV) from bovine herpes virus-1 (BHV-1). Groups of five animals were then given either 2, 3, 4, or 5 doses of interleukin-2 (IL-2) (0.5 microgram/kg) at 12-hr intervals. Animals that received no IL-2 exhibited specific immune responses that are typical for BHV-1 infection, i.e. enhanced specific cytotoxicity, lymphocyte proliferative responses to gIV, and increased gIV-specific (ELISA) and virus-neutralizing antibodies. Treatment of animals with five doses of IL-2 significantly augmented all of these responses except serum neutralization (P less than 0.05). Furthermore, the dose of IL-2 that was selected did not induce any non-specific responses, i.e. hypergamma-globulinaemia, changes in blood chemistry, increased lymphokine-activated killer (LAK) cell activity, changes in mitogen responsiveness or alterations in the phenotypic profile of circulating lymphocytes. Nor were there any clinical changes associated with IL-2 therapy (e.g. depression, pyrexia, diarrhea). Animals that were treated with less than five doses of IL-2 also exhibited elevated immune responses, but they were not significantly different from untreated immunized controls. Interestingly, animals given five doses of IL-2 responded to minor contaminants present in the gIV preparation. This allows speculation that this dose regimen of IL-2 is not only a potent adjuvant for conventional vaccine immunizing doses, but will also allow the use of minute quantities of antigen for immunization. |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1384640</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16071141</sourcerecordid><originalsourceid>FETCH-LOGICAL-p352t-780832692dbf2d29a2a0b45e40b712993c0f326249ea897c84b7d21bb16ad1973</originalsourceid><addsrcrecordid>eNqNkU1LwzAch4Moc04_gtCDeCvkPc1FkOHLYOhFzyVJUxdtk9o0hX17KxtDT3oKf56HHw_kCMwR4SzHjItjMIcQyRwXkJ2Csxjfp5NAxmZghjgnUIg5eFq1bfKhC4P1g1ODCz4LdabD6LzNNrbvbMxG16eYxaSTd0M2KmOc36l6mzk_2L6x6cP5HJ-Dk1o10V7s3wV4vb97WT7m6-eH1fJ2nXeE4SEXBSwI5hJXusYVlgorqCmzFGqBsJTEwHrimEqrCilMQbWoMNIacVUhKcgC3Ox2u6RbW5kpvldN2fWuVf22DMqVv4l3m_ItjCUiBeUUTgPX-4E-fCYbh7J10dimUd6GFEuBOWRU0j9FxKFAiKL_iBwL8d1--bP9EL3_k4lf7bmKRjV1r7xx8aAxJArKIPkCrMSWvw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16062777</pqid></control><display><type>article</type><title>Immunopotentiation of bovine herpes virus subunit vaccination by interleukin-2</title><source>Open Access: PubMed Central</source><creator>HUGHES, H. P. A ; CAMPOS, M ; GODSON, D. L ; VAN DRUNEN LITTEL-VAN DEN HURK, S ; MCDOUGALL, L ; RAPIN, N ; ZAMB, T ; BABIUK, L. A</creator><creatorcontrib>HUGHES, H. P. A ; CAMPOS, M ; GODSON, D. L ; VAN DRUNEN LITTEL-VAN DEN HURK, S ; MCDOUGALL, L ; RAPIN, N ; ZAMB, T ; BABIUK, L. A</creatorcontrib><description>Cattle were immunized with glycoprotein IV (gIV) from bovine herpes virus-1 (BHV-1). Groups of five animals were then given either 2, 3, 4, or 5 doses of interleukin-2 (IL-2) (0.5 microgram/kg) at 12-hr intervals. Animals that received no IL-2 exhibited specific immune responses that are typical for BHV-1 infection, i.e. enhanced specific cytotoxicity, lymphocyte proliferative responses to gIV, and increased gIV-specific (ELISA) and virus-neutralizing antibodies. Treatment of animals with five doses of IL-2 significantly augmented all of these responses except serum neutralization (P less than 0.05). Furthermore, the dose of IL-2 that was selected did not induce any non-specific responses, i.e. hypergamma-globulinaemia, changes in blood chemistry, increased lymphokine-activated killer (LAK) cell activity, changes in mitogen responsiveness or alterations in the phenotypic profile of circulating lymphocytes. Nor were there any clinical changes associated with IL-2 therapy (e.g. depression, pyrexia, diarrhea). Animals that were treated with less than five doses of IL-2 also exhibited elevated immune responses, but they were not significantly different from untreated immunized controls. Interestingly, animals given five doses of IL-2 responded to minor contaminants present in the gIV preparation. This allows speculation that this dose regimen of IL-2 is not only a potent adjuvant for conventional vaccine immunizing doses, but will also allow the use of minute quantities of antigen for immunization.</description><identifier>ISSN: 0019-2805</identifier><identifier>EISSN: 1365-2567</identifier><identifier>PMID: 1663077</identifier><identifier>CODEN: IMMUAM</identifier><language>eng</language><publisher>Oxford: Blackwell</publisher><subject>Adjuvants, Immunologic ; Animals ; Antibodies, Viral - biosynthesis ; Biological and medical sciences ; Cattle ; Cell Division - immunology ; Cytotoxicity, Immunologic - immunology ; Epidemiology ; Fundamental and applied biological sciences. Psychology ; Glycoproteins - immunology ; Herpesvirus 1, Bovine - immunology ; Interleukin-2 - immunology ; Microbiology ; Recombinant Proteins - immunology ; T-Lymphocytes - immunology ; Viral Vaccines - immunology ; Virology</subject><ispartof>Immunology, 1991-11, Vol.74 (3), p.461-466</ispartof><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1384640/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1384640/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,315,733,786,790,891,53827,53829</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=5178450$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1663077$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HUGHES, H. P. A</creatorcontrib><creatorcontrib>CAMPOS, M</creatorcontrib><creatorcontrib>GODSON, D. L</creatorcontrib><creatorcontrib>VAN DRUNEN LITTEL-VAN DEN HURK, S</creatorcontrib><creatorcontrib>MCDOUGALL, L</creatorcontrib><creatorcontrib>RAPIN, N</creatorcontrib><creatorcontrib>ZAMB, T</creatorcontrib><creatorcontrib>BABIUK, L. A</creatorcontrib><title>Immunopotentiation of bovine herpes virus subunit vaccination by interleukin-2</title><title>Immunology</title><addtitle>Immunology</addtitle><description>Cattle were immunized with glycoprotein IV (gIV) from bovine herpes virus-1 (BHV-1). Groups of five animals were then given either 2, 3, 4, or 5 doses of interleukin-2 (IL-2) (0.5 microgram/kg) at 12-hr intervals. Animals that received no IL-2 exhibited specific immune responses that are typical for BHV-1 infection, i.e. enhanced specific cytotoxicity, lymphocyte proliferative responses to gIV, and increased gIV-specific (ELISA) and virus-neutralizing antibodies. Treatment of animals with five doses of IL-2 significantly augmented all of these responses except serum neutralization (P less than 0.05). Furthermore, the dose of IL-2 that was selected did not induce any non-specific responses, i.e. hypergamma-globulinaemia, changes in blood chemistry, increased lymphokine-activated killer (LAK) cell activity, changes in mitogen responsiveness or alterations in the phenotypic profile of circulating lymphocytes. Nor were there any clinical changes associated with IL-2 therapy (e.g. depression, pyrexia, diarrhea). Animals that were treated with less than five doses of IL-2 also exhibited elevated immune responses, but they were not significantly different from untreated immunized controls. Interestingly, animals given five doses of IL-2 responded to minor contaminants present in the gIV preparation. This allows speculation that this dose regimen of IL-2 is not only a potent adjuvant for conventional vaccine immunizing doses, but will also allow the use of minute quantities of antigen for immunization.</description><subject>Adjuvants, Immunologic</subject><subject>Animals</subject><subject>Antibodies, Viral - biosynthesis</subject><subject>Biological and medical sciences</subject><subject>Cattle</subject><subject>Cell Division - immunology</subject><subject>Cytotoxicity, Immunologic - immunology</subject><subject>Epidemiology</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Glycoproteins - immunology</subject><subject>Herpesvirus 1, Bovine - immunology</subject><subject>Interleukin-2 - immunology</subject><subject>Microbiology</subject><subject>Recombinant Proteins - immunology</subject><subject>T-Lymphocytes - immunology</subject><subject>Viral Vaccines - immunology</subject><subject>Virology</subject><issn>0019-2805</issn><issn>1365-2567</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><recordid>eNqNkU1LwzAch4Moc04_gtCDeCvkPc1FkOHLYOhFzyVJUxdtk9o0hX17KxtDT3oKf56HHw_kCMwR4SzHjItjMIcQyRwXkJ2Csxjfp5NAxmZghjgnUIg5eFq1bfKhC4P1g1ODCz4LdabD6LzNNrbvbMxG16eYxaSTd0M2KmOc36l6mzk_2L6x6cP5HJ-Dk1o10V7s3wV4vb97WT7m6-eH1fJ2nXeE4SEXBSwI5hJXusYVlgorqCmzFGqBsJTEwHrimEqrCilMQbWoMNIacVUhKcgC3Ox2u6RbW5kpvldN2fWuVf22DMqVv4l3m_ItjCUiBeUUTgPX-4E-fCYbh7J10dimUd6GFEuBOWRU0j9FxKFAiKL_iBwL8d1--bP9EL3_k4lf7bmKRjV1r7xx8aAxJArKIPkCrMSWvw</recordid><startdate>19911101</startdate><enddate>19911101</enddate><creator>HUGHES, H. P. A</creator><creator>CAMPOS, M</creator><creator>GODSON, D. L</creator><creator>VAN DRUNEN LITTEL-VAN DEN HURK, S</creator><creator>MCDOUGALL, L</creator><creator>RAPIN, N</creator><creator>ZAMB, T</creator><creator>BABIUK, L. A</creator><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19911101</creationdate><title>Immunopotentiation of bovine herpes virus subunit vaccination by interleukin-2</title><author>HUGHES, H. P. A ; CAMPOS, M ; GODSON, D. L ; VAN DRUNEN LITTEL-VAN DEN HURK, S ; MCDOUGALL, L ; RAPIN, N ; ZAMB, T ; BABIUK, L. A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p352t-780832692dbf2d29a2a0b45e40b712993c0f326249ea897c84b7d21bb16ad1973</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Adjuvants, Immunologic</topic><topic>Animals</topic><topic>Antibodies, Viral - biosynthesis</topic><topic>Biological and medical sciences</topic><topic>Cattle</topic><topic>Cell Division - immunology</topic><topic>Cytotoxicity, Immunologic - immunology</topic><topic>Epidemiology</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Glycoproteins - immunology</topic><topic>Herpesvirus 1, Bovine - immunology</topic><topic>Interleukin-2 - immunology</topic><topic>Microbiology</topic><topic>Recombinant Proteins - immunology</topic><topic>T-Lymphocytes - immunology</topic><topic>Viral Vaccines - immunology</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HUGHES, H. P. A</creatorcontrib><creatorcontrib>CAMPOS, M</creatorcontrib><creatorcontrib>GODSON, D. L</creatorcontrib><creatorcontrib>VAN DRUNEN LITTEL-VAN DEN HURK, S</creatorcontrib><creatorcontrib>MCDOUGALL, L</creatorcontrib><creatorcontrib>RAPIN, N</creatorcontrib><creatorcontrib>ZAMB, T</creatorcontrib><creatorcontrib>BABIUK, L. A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HUGHES, H. P. A</au><au>CAMPOS, M</au><au>GODSON, D. L</au><au>VAN DRUNEN LITTEL-VAN DEN HURK, S</au><au>MCDOUGALL, L</au><au>RAPIN, N</au><au>ZAMB, T</au><au>BABIUK, L. A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunopotentiation of bovine herpes virus subunit vaccination by interleukin-2</atitle><jtitle>Immunology</jtitle><addtitle>Immunology</addtitle><date>1991-11-01</date><risdate>1991</risdate><volume>74</volume><issue>3</issue><spage>461</spage><epage>466</epage><pages>461-466</pages><issn>0019-2805</issn><eissn>1365-2567</eissn><coden>IMMUAM</coden><notes>ObjectType-Article-2</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-1</notes><notes>content type line 23</notes><notes>ObjectType-Article-1</notes><notes>ObjectType-Feature-2</notes><abstract>Cattle were immunized with glycoprotein IV (gIV) from bovine herpes virus-1 (BHV-1). Groups of five animals were then given either 2, 3, 4, or 5 doses of interleukin-2 (IL-2) (0.5 microgram/kg) at 12-hr intervals. Animals that received no IL-2 exhibited specific immune responses that are typical for BHV-1 infection, i.e. enhanced specific cytotoxicity, lymphocyte proliferative responses to gIV, and increased gIV-specific (ELISA) and virus-neutralizing antibodies. Treatment of animals with five doses of IL-2 significantly augmented all of these responses except serum neutralization (P less than 0.05). Furthermore, the dose of IL-2 that was selected did not induce any non-specific responses, i.e. hypergamma-globulinaemia, changes in blood chemistry, increased lymphokine-activated killer (LAK) cell activity, changes in mitogen responsiveness or alterations in the phenotypic profile of circulating lymphocytes. Nor were there any clinical changes associated with IL-2 therapy (e.g. depression, pyrexia, diarrhea). Animals that were treated with less than five doses of IL-2 also exhibited elevated immune responses, but they were not significantly different from untreated immunized controls. Interestingly, animals given five doses of IL-2 responded to minor contaminants present in the gIV preparation. This allows speculation that this dose regimen of IL-2 is not only a potent adjuvant for conventional vaccine immunizing doses, but will also allow the use of minute quantities of antigen for immunization.</abstract><cop>Oxford</cop><pub>Blackwell</pub><pmid>1663077</pmid><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0019-2805 |
| ispartof | Immunology, 1991-11, Vol.74 (3), p.461-466 |
| issn | 0019-2805 1365-2567 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1384640 |
| source | Open Access: PubMed Central |
| subjects | Adjuvants, Immunologic Animals Antibodies, Viral - biosynthesis Biological and medical sciences Cattle Cell Division - immunology Cytotoxicity, Immunologic - immunology Epidemiology Fundamental and applied biological sciences. Psychology Glycoproteins - immunology Herpesvirus 1, Bovine - immunology Interleukin-2 - immunology Microbiology Recombinant Proteins - immunology T-Lymphocytes - immunology Viral Vaccines - immunology Virology |
| title | Immunopotentiation of bovine herpes virus subunit vaccination by interleukin-2 |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-23T05%3A28%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunopotentiation%20of%20bovine%20herpes%20virus%20subunit%20vaccination%20by%20interleukin-2&rft.jtitle=Immunology&rft.au=HUGHES,%20H.%20P.%20A&rft.date=1991-11-01&rft.volume=74&rft.issue=3&rft.spage=461&rft.epage=466&rft.pages=461-466&rft.issn=0019-2805&rft.eissn=1365-2567&rft.coden=IMMUAM&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E16071141%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p352t-780832692dbf2d29a2a0b45e40b712993c0f326249ea897c84b7d21bb16ad1973%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=16062777&rft_id=info:pmid/1663077&rfr_iscdi=true |